Latest Headlines

  1. Quest Diagnostics To Offer FDA-Cleared Fujirebio Blood Test For Alzheimer's Disease 7/9/2025

    Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.

  2. Claret Bioscience And Hamilton Company Partner To Automate NGS Library Prep Workflows 7/9/2025

    Claret Bioscience, a pioneer in next-generation sequencing (NGS) library preparation technologies for challenging samples, and Hamilton Company, a global leader in precision laboratory automation, are proud to announce a strategic co-promotion initiative.

  3. Volition Announces Groundbreaking Lateral Flow Test For Point-Of-Care Quantification Of Nucleosomes 7/8/2025

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device.

  4. AgileBio Brings Back Dymo–LabCollector Integration In Partnership With GA International 7/8/2025

    Labeling is essential in laboratory operations. From frozen samples to daily experiments, collection of samples and shipping, printing labels directly from LabCollector makes the process faster and more reliable.

  5. PathAI Launches Precision Pathology Network To Advance AI-Powered Pathology 7/8/2025

    PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today unveiled the launch of the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories powered by PathAI’s AISight®1 Image Management System (IMS).

  6. Invivoscribe Expands Flow Cytometry Services To Accelerate CAR-T Immunotherapy Development And Regulatory Readiness With The Initiation Of CERo Therapeutics Phase 1 Clinical Trial 7/8/2025

    Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms.

  7. Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition And Platform Rollout 7/7/2025

    Bio-Rad Laboratories, Inc. a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital PCR (ddPCR) platforms.

  8. MicroGenDX Transforms Infectious Disease Diagnostics With Innovative 24-Hour Testing Technology 7/7/2025

    MicroGenDX, a national leader in molecular diagnostics, announces the integration of the Illumina MiSeq i100 Plus platform into its lab operations.

  9. Cyrex Launches Biomeburden™ For Immune Sensitivity Testing Of Microbial, Yeast And Mold Triggers 7/7/2025

    Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, today announced the launch of BiomeBurden™, its newest innovation in gut biome testing.

  10. Belay Diagnostics Announces The Validation Of Vantage™ Assay For Evaluation Of MGMT Promoter Methylation In Cerebrospinal Fluid 7/7/2025

    Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced the results of the analytical validation study of the Belay Vantage™ assay for detection of MGMT (Methylation of the O6-methylguanine-DNA methyl-transferase) promoter methylation in cerebrospinal fluid (CSF) for primary and metastatic CNS cancers as reported in Cancer Genetics.